Evidence map›Paper›PMID 24831005›Full record

ArticleThe Journal of biological chemistry2014

Tyrosine 308 is necessary for ligand-directed Gs protein-biased signaling of β2-adrenoceptor.

Anthony Yiu-Ho Woo, Krzysztof Jozwiak, Lawrence Toll, Mary J Tanga, Joseph A Kozocas, Lucita Jimenez, Ying Huang, Ying Song, Anita Plazinska, Karolina Pajak and 4 more

Abstract read
In one paragraph

Article in The Journal of biological chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Discovery of β-arrestin-biased βActa pharmacologica Sinica · 2019
    Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Concurrent activation of βCellular signalling · 2017
    Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Anthony Yiu-Ho WooFrom the Key Laboratory of Chemical Genomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen 518055, China, the Institute of Molecular Medicine, Centers for Life Sciences, Peking University, Beijing 100871, China, the Laboratory of Cardiovascular Science and yiuhowoo@pkusz.edu.cn.
Krzysztof Jozwiakthe Department of Chemistry, Medical University of Lublin, Lublin, Poland.
Lawrence Tollthe Torrey Pines Institute for Molecular Studies, Port St. Lucie, Florida 34987, and.
Mary J TangaSRI International, Menlo Park, California 94025.
Joseph A KozocasSRI International, Menlo Park, California 94025.
Lucita JimenezSRI International, Menlo Park, California 94025.
Ying HuangFrom the Key Laboratory of Chemical Genomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen 518055, China, the Institute of Molecular Medicine, Centers for Life Sciences, Peking University, Beijing 100871, China.
Ying SongFrom the Key Laboratory of Chemical Genomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen 518055, China, the Institute of Molecular Medicine, Centers for Life Sciences, Peking University, Beijing 100871, China.
Anita Plazinskathe Department of Chemistry, Medical University of Lublin, Lublin, Poland.
Karolina Pajakthe Department of Chemistry, Medical University of Lublin, Lublin, Poland.
Rajib K PaulLaboratory of Clinical Investigation, NIA, National Institutes of Health, Baltimore, Maryland 21224.
Michel BernierLaboratory of Clinical Investigation, NIA, National Institutes of Health, Baltimore, Maryland 21224.
Irving W WainerLaboratory of Clinical Investigation, NIA, National Institutes of Health, Baltimore, Maryland 21224.
Rui-Ping Xiaothe Institute of Molecular Medicine, Centers for Life Sciences, Peking University, Beijing 100871, China, xiaor@pku.edu.cn.

Funding

Intramural NIH HHSNIA NIH HHS N01 AG031009
6 · The paper itself

Abstract

Interaction of a given G protein-coupled receptor to multiple different G proteins is a widespread phenomenon. For instance, β2-adrenoceptor (β2-AR) couples dually to Gs and Gi proteins. Previous studies have shown that cAMP-dependent protein kinase (PKA)-mediated phosphorylation of β2-AR causes a switch in receptor coupling from Gs to Gi. More recent studies have demonstrated that phosphorylation of β2-AR by G protein-coupled receptor kinases, particularly GRK2, markedly enhances the Gi coupling. We have previously shown that although most β2-AR agonists cause both Gs and Gi activation, (R,R')-fenoterol preferentially activates β2-AR-Gs signaling. However, the structural basis for this functional selectivity remains elusive. Here, using docking simulation and site-directed mutagenesis, we defined Tyr-308 as the key amino acid residue on β2-AR essential for Gs-biased signaling. Following stimulation with a β2-AR-Gs-biased agonist (R,R')-4'-aminofenoterol, the Gi disruptor pertussis toxin produced no effects on the receptor-mediated ERK phosphorylation in HEK293 cells nor on the contractile response in cardiomyocytes expressing the wild-type β2-AR. Interestingly, Y308F substitution on β2-AR enabled (R,R')-4'-aminofenoterol to activate Gi and to produce these responses in a pertussis toxin-sensitive manner without altering β2-AR phosphorylation by PKA or G protein-coupled receptor kinases. These results indicate that, in addition to the phosphorylation status, the intrinsic structural feature of β2-AR plays a crucial role in the receptor coupling selectivity to G proteins. We conclude that specific interactions between the ligand and the Tyr-308 residue of β2-AR stabilize receptor conformations favoring the receptor-Gs protein coupling and subsequently result in Gs-biased agonism.

Indexed as

Adrenergic beta-2 Receptor AgonistsAmino Acid SubstitutionAnimalsExtracellular Signal-Regulated MAP KinasesHEK293 CellsHumansMaleMiceMice, KnockoutMutation, MissenseMyocytes, CardiacPhosphorylationProtein StabilityRatsRats, Sprague-DawleyReceptors, Adrenergic, beta-2ADRB2 protein, humanAdrenergic beta-2 Receptor AgonistsExtracellular Signal-Regulated MAP KinasesReceptors, Adrenergic, beta-2TyrosineAdrenergic ReceptorCardiomyocyte ContractionCardiovascularFunctional SelectivityG Protein-coupled Receptor (GPCR)Molecular DockingMolecular PharmacologySignal TransductionSite-directed Mutagenesis

Identifiers

PMID24831005
PMCPMC4094047

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.